Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2026 16:02 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second...
February 18, 2026 10:28 ET | Source: Research and Markets

JAK Inhibitors Competitive Landscape Report 2026: Comprehensive Insights on 40+ Companies and 45+ Drugs by Company, Product Type, Development Stage, Administration Route, Molecule Type

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "JAK Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report delivers a detailed analysis of over...
February 18, 2026 09:33 ET | Source: Stoked Bio Inc.

Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease

Stoked Bio, a Canadian biotech company, will lead the development of Enterololin, a promising antibiotic, as a potential therapeutic for Crohn’s disease.
February 17, 2026 06:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well...
February 17, 2026 06:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug...
February 12, 2026 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup...
February 11, 2026 07:00 ET | Source: Royalty Pharma plc

Royalty Pharma Reports Q4 and Full Year 2025 Results

Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in...
February 05, 2026 07:18 ET | Source: Research and Markets

Crohn's Disease (Regional Enteritis) Global Clinical Trials Market Review 2025: G7 and E7 Activities, Trial Status, Sponsor Insights, Enrollment Trends, Company Listings, Unaccomplished Trials

Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Crohn's Disease (Regional Enteritis) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.This...
January 28, 2026 07:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding...
January 13, 2026 12:30 ET | Source: AstuteAnalytica India Pvt. Ltd.

Exosome Research Market Projected to Reach US$ 2,491.42 Million by 2035, Supported by Expanding Therapeutic Development Pipelines | Astute Analytica

Chicago, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The global exosome research market was valued at US$ 280.70 million in 2025 and is expected to reach US$ 2,491.42 million by 2035 at a CAGR of 24.4% over...